Remember The Basics: Dosing, Placebo Issues Recur In FDA Reviews
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Fundamental trial design issues, from the selection of doses to the use of placebo controls, recur as problems in FDA reviews of new drugs. Post-market studies can remedy missing data, but at a cost.
You may also be interested in...
FDA’s Regulatory Flexibility On Display In Review Of Innovative Agents
Regulatory flexibility is the backbone of FDA’s success in efficiently reviewing new drugs and biologics, especially on the frontiers of unmet medical needs, Pharmaceutical Approvals Monthly’s 2011 series of drug review profiles shows.
Keeping Track: Enhertu Brings Anti-HER2 Therapy To Lung Cancer; Novaliq Platform Supports Two Dry Eye NDAs
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Keeping Track: Enhertu, Nubeqa Grow With RTOR; Interchangeable Cimerli And Another Nuplazid CRL
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker